肿瘤反义治疗研究进展
被引量：1
The development of antisense therapy in cancer
摘要
肿瘤反义治疗是以反义寡核苷酸为基础的一种基因治疗方法 ,经过近二十几年的发展 ,反义寡核苷酸以其高特异性和低毒副作用等优良特性 ,正成为新一代抗肿瘤药物的主力军。现着重介绍反义技术的原理、反义寡核苷酸在临床应用的进展及具有临床应用前途的反义靶标。
出处
《国外医学（肿瘤学分册）》
2004年第9期674-677,共4页
Foreign Medical Sciences (Cancer Section)
参考文献27
-
1Jansen B, Zangemeister Wittke U. Antisense therapy for cancer-the time of truth. Lancet Oncol,2002,3( 11 ) :672-683.
-
2Donis Keller H. Site specific enzymatic cleavage of RNA. Nucleic Acids Rea,1979,7 (1): 179-192.
-
3Milner N, Mir KU, Southern EM. Selecting effective antisense reagents on combinatorial oligonucleotide arrays. Nat Biotechnol, 1997, 15 (6):537-541.
-
4Ho SP, Bao Y, Lesher T, et al. Mapping of RNA accessible sites for antisense experiments with oligonucleotide libraries. Nat Biotechnol, 1998,16(1): 59-63.
-
5Mathews DH, Sabina J, Zuker M, et al. Expanded sequence dependence of thermodynaymic parameters improves prediction of RNA secondary structure. J Mol Biol, 1999,288 (5): 911-940.
-
6Webb A, Cunningham D, Cotter F, et al. BCL-2 antisense therapy in patients with non-Hodgkdn lymphoma. Lancet, 1997,349 (9059): 1137-1141.
-
7Jansen B, Schlagbauer Wadl H, Brown BD, et al. BCL-2 antisense therapy chemosensitizes human melanoma in SCID mice. Nat Med, 1998, 4(2): 232-234.
-
8Jansen B, Wacheck V, Heere Ress E, et al. Chemosensitisation of malignant melanoma by BCL-2 antisense therapy. Lancet, 2000, 356(9243): 1728-1733.
-
9Yazaki T, Ahmad S, Chahlavi A, et al. Treatment of glioblastoma U-87by systemic administration of an antisense protein kinase C-alpha phosphorothioate oligodeoxynucleotide. Mol Pharmacol, 1996,50 (2): 236-242.
-
10Howe LR, Leevers SJ, Gomez N, et al. Activation of the MAP kinase pathway by the protein kinase raf. Cell, 1992,71 (2): 335-342.
同被引文献9
-
1黄明主,李杰.基因技术在逆转肿瘤细胞多药耐药性上的应用[J].肿瘤,2004,24(6):608-610. 被引量：7
-
2周友珍,李红霞,张文晶,魏丽惠.人卵巢癌拓扑替康耐药细胞株SKOV3/TPT的建立及生物学特性的研究[J].解放军医学杂志,2005,30(8):715-717. 被引量：3
-
3Oguri T,Isobe T,Fujitaka K,et al.Association between expression of the MRP3 gene and exposure to platinum drugs in lung cancer[J].Int J Cancer,2001,93(4):584～589
-
4Uchiumi T,Hinoshita E,Haga S,et al.Isolation of a novel human canalicular multispecific organic anion transporter,cMOAT2/MRP3,and its expression in cisplatin-resistant cancer cells with decreased ATP-dependent drug transport[J].Biochem Biophys Res,1998,252(1):103～110
-
5Young LC,Campling BG,Cole SP,et al.Mlultidrug resistance proteins MRP3,MRP1,and MRP2 in lung cancer:correlation of protein levels with drug response and messenger RNA levels[J].Clinical Cancer Res,2001,7(6):1798～1804
-
6Cummings J,Zelcer N,Allen JD,et al.Glucuronidation as a mechanism of intrinsic drug resistance in colon cancer cells:contribution of drug transport proteins[J[.Biochem Pharmacol,2004,67(1):31～39
-
7Herzog TJ.Update on the role of topotecan in the treatment of recurrent ovarian cancer[J].Oncogene,2002,7(Suppl 5):3 ～ 10
-
8Rasheed ZA,Rubin EH.Mechanisms of resistance to topoisomerase Ⅰ-targeting drugs[J].Oncogene,2003,22(47):7296 ～ 7304
-
9Zeng H,Bain LJ,Besinky MG,et al.Expression of multidrug resistance protein-3 (multispecific organic anion transporter-D)in human embryonic kidney 293 cells confers resistance to anticancer agents[J].Cancer Res,1999,59(23):5964～5967
-
1李文瑜,张洹.反义治疗与白血病靶基因研究进展[J].中国病理生理杂志,2000,16(8):764-768.
-
2张彦,贾伟丽.Bcl-2反义治疗与肿瘤关系进展[J].现代肿瘤医学,2011,19(2):382-385. 被引量：8
-
3姚培元,只达石,秦进喜.神经胶质瘤的反义治疗研究进展[J].中华神经外科杂志,1999,15(2):123-125. 被引量：3
-
4米淑玲,苏艳艳,尹利荣,马洪达,孙俊杰.P27,P73和CyclinD1蛋白在子宫内膜癌中表达的相关性[J].国际妇产科学杂志,2010,37(4):284-287.
-
5胡明球,李月明.Ki-67蛋白与泌尿系肿瘤[J].国外医学（泌尿系统分册）,2004,24(6):773-777. 被引量：2
-
6王颖,陈昶泷,黄绪琼,夏建川,张建华.TPD52基因与原发性肝细胞癌患者预后相关性分析[J].中国医药生物技术,2015,10(6):507-513.
-
7邹文,胡春宏,郭凯平,何燕.p27蛋白在乳腺癌中的表达及预后关系[J].肿瘤防治杂志,2003,10(2):137-139. 被引量：2
-
8张虹,谢潇潇.X连锁凋亡抑制蛋白在卵巢肿瘤中的表达及意义[J].天津医药,2008,36(12):945-947. 被引量：1
-
9江燕,张洪福,曹立宇,李昊.食管鳞状细胞癌Fhit蛋白表达与吸烟的关系[J].安徽医科大学学报,2005,40(1):38-40. 被引量：2
-
10王新平,曾亚,申月明,王赛,王俊,易艳容.Aurora—B蛋白在胃癌组织中的表达及意义[J].医学临床研究,2017,34(1):105-108.
